Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for ...

Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data demonstrating compelling complete response rate in third-line or ...

– Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse – Genentech, a ...

Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...

Dr Kami Maddocks shares highlights from ASH 2025, including how the phase 3 EPCORE FL‑1 trial, adding a bispecific antibody to R2 in second‑line or later follicular lymphoma, showed significantly ...

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the ...

Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option ...

Thanks to a clinical trial for follicular lymphoma at MSK, Michael is able to spend time with family, including his granddaughter, Natalia. Retired New York City police officer Michael T. had grown ...

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not ...

The safety profile of EPKINLY + R 2 in the EPCORE FL-1 study was generally consistent with the known safety profiles of the individual regimens (epcoritamab and R 2). The most common (≥ 20%) adverse ...

Epcoritamab-bysp, combined with rituximab and lenalidomide, is FDA-approved for relapsed follicular lymphoma, marking a significant advancement in second-line treatment. The EPCORE FL-1 trial showed a ...